Approval of Folsyra EQL Pharma

The pharmaceutical Folsyra EQL Pharma, tablet 1 mg, has been approved for sale in Sweden by the Medical Products Agency.

Folsyra EQL Pharma is a prescription drug used to treat folate deficiency or an increased folate need at, for example, gluten intolerance or during pregnancy.

Folsyra EQL Pharma contains folic acid, a substance which in the body is converted into folate (vitamin B9), a vitamin that is naturally obtained through the diet, mainly from vegetables and bread. The market for prescription folic acid 1 mg is approximately SEK 23 million in total annual sales in Sweden.

The product is expected to be launched during EQL Pharma's first financial quarter, 2021/22.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 18 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2020 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 9 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.